Rosalie A. Scholtes

Rosalie A. Scholtes

Auto-generated profile, based on publicly available information

Rosalie A. Scholtes

Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, VU University Medical Center , Amsterdam

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
TSTaha Sen
Taha Sen
RSRosalie Scholtes
Rosalie Scholtes
PGPeter J. Greasley
Peter J. Greasley
DCDavid Z. I. Cherney
David Z. I. Cherney
CDClaire Dekkers
Claire Dekkers
HHHiddo Heerspink
Hiddo Heerspink
Aims: To assess the effect of sodium‐glucose cotransporter‐2 inhibitor dapagliflozin on natriuresis, blood pressure (BP) and volume status in patients with chronic kidney disease (CKD) without diabetes. Materials and methods: We performed a mechanistic open‐label study (DAPASALT) to evaluate the effects of dapagliflozin on 24‐hour sodium excretion, 24‐hour BP, extracellular volume, and markers of volume status during a standardized sodium diet (150 mmol/d) in six patients with CKD. In parallel, in a placebo‐controlled double‐blind crossover trial (DIAMOND), we determined the effects of 6 weeks of dapagliflozin on markers of volume status in 53 patients with CKD. Results: In DAPASALT (mean age 65 years, mean estimated glomerular filtration rate [eGFR] 39.4 mL/min/1.73 m 2 , median urine albumin:creatinine ratio [UACR] 111 mg/g), dapagliflozin did not change 24‐hour sodium and volume excretion during 2 weeks of treatment. Dapagliflozin was associated with a modest increase in 24‐hour glucose excretion on Day 4, which persisted at Day 14 and reversed to baseline after discontinuation. Mean 24‐hour systolic BP decreased by −9.3 (95% confidence interval [CI] −19.1, 0.4) mmHg after 4 days and was sustained at Day 14 and at wash‐out. Renin, angiotensin II, urinary aldosterone and copeptin levels increased from baseline. In DIAMOND (mean age 51 years, mean eGFR 59.0 mL/min/1.73 m 2 , median UACR 608 mg/g), compared to placebo, dapagliflozin increased plasma renin (38.5 [95% CI 7.4, 78.8]%), aldosterone (19.1 [95% CI −5.9, 50.8]%), and copeptin levels (7.3 [95% CI 0.1, 14.5] pmol/L). Conclusions: During a standardized sodium diet, dapagliflozin decreased BP but did not increase 24‐hour sodium and volume excretion. The lack of increased natriuresis and diuresis may be attributed to activation of intra‐renal compensatory mechanisms to prevent excessive water loss.

4 March 2022 in Kidney International Reports
Verified
Journal Article
Open access
RSRosalie A. Scholtes
Rosalie A. Scholtes
MMMarcel H.A. Muskiet
Marcel H.A. Muskiet
MBMichiel J.B. van Baar
Michiel J.B. van Baar
AHAnne C. Hesp
Anne C. Hesp
PGPeter J. Greasley
Peter J. Greasley
DRDaniel H. Van Raalte
Daniel H. Van Raalte
Proximal tubule sodium uptake is diminished following sodium glucose cotransporter 2 (SGLT2) inhibition. We previously showed that during SGLT2 inhibition, the kidneys adapt by increasing sodium uptake at distal tubular segments, thereby maintaining body sodium balance. Despite continuous glycosuria, we detected no increased urine volumes. We therefore assessed the adaptive renal responses to prevent excessive fluid loss. We conducted a mechanistic open-label study in people with type 2 diabetes mellitus with preserved kidney function, who received a standardized sodium intake (150 mmol/d) to evaluate the effects of dapagliflozin on renin-angiotensin-aldosterone system (RAAS) hormones, volume-related biomarkers, urinary albumin-to-creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR), at start of treatment (day 4), end of treatment (day 14), and follow-up (day 18). A total of 14 people were enrolled. Plasma renin and angiotensin II and urinary aldosterone and angiotensinogen were acutely and persistently increased during treatment with dapagliflozin. Plasma copeptin level was numerically increased after 4 days (21%). Similarly, fractional urea excretion was significantly decreased at start of treatment (−17%). Free water clearance was significantly decreased after 4 days (−74%) and 14 days (−41%). All changes reversed after dapagliflozin discontinuation. Dapagliflozin-induced osmotic diuresis triggers kidney adaptive mechanisms to maintain volume and sodium balance in people with type 2 diabetes and preserved kidney function. ClinicalTrials.gov (identification: NCT03152084).

6 March 2019 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
RSRosalie A. Scholtes
Rosalie A. Scholtes
MBMichaël J. B. van Baar
Michaël J. B. van Baar
YLYuliya Lytvyn
Yuliya Lytvyn
PBPetter Bjornstad
Petter Bjornstad
MNMax Nieuwdorp
Max Nieuwdorp
DRDaniel H. Van Raalte
Daniel H. Van Raalte
Sodium glucose cotransporter (SGLT)‐2 inhibitors are the newest addition to our treatment armamentarium for the management of hyperglycemia in type 2 diabetes. Glucose‐lowering per se reduces the risk of microvascular complications, but not the risk of cardiovascular disease, including heart failure and cardiovascular mortality. Also, even when embedded in optimal cardiovascular prevention, a large residual risk remains with respect to progression of diabetic kidney disease. SGLT‐2 inhibitors lower blood glucose levels by inducing glucosuria. Through various proposed mechanisms, among which diuretic and natriuretic effects, SGLT‐2 inhibitors decrease heart failure hospitalization, reduce cardiovascular mortality, and mitigate progression of diabetic kidney disease. In this perspective, we will discuss the glucose‐lowering and other protective effects of SGLT‐2 inhibitors on the cardiorenal axis, both in primary and secondary prevention. By comparing the glycemic and pleiotropic effects of these agents to other glucose‐lowering drugs, we will address questions around whether SGLT‐2 inhibitors should be considered primarily as glucose‐lowering agents, cardiorenal drugs or both.

6 December 2020 in Nephrology
Verified
Journal Article
Open access
PDF file
RSRosalie A. Scholtes
Rosalie A. Scholtes
MBMichaël J. B. van Baar
Michaël J. B. van Baar
MKMegan D. Kok
Megan D. Kok
PBPetter Bjornstad
Petter Bjornstad
DCDavid Z. I. Cherney
David Z. I. Cherney
DRDaniel H. Van Raalte
Daniel H. Van Raalte
Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortality and attenuate hard renal outcomes in patients with type 2 diabetes (T2D). Underlying mechanisms explaining these renal benefits may be mediated by decreased glomerular hypertension, possibly by vasodilation of the post‐glomerular arteriole. People with T2D often receive several different drugs, some of which could also impact the renal vasculature, and could therefore modify both renal efficacy and safety of SGLT2 inhibition. The most commonly prescribed drugs that could interact with SGLT2 inhibitors on renal haemodynamic function include renin‐angiotensin system inhibitors, calcium channel blockers and diuretics. Herein, we review the effects of these drugs on renal haemodynamic function in people with T2D and focus on studies that measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) with gold‐standard techniques. In addition, we posit, based on these observations, potential interactions with SGLT2 inhibitors with an emphasis on efficacy and safety.

19 November 2019 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
RSRosalie A. Scholtes
Rosalie A. Scholtes
DRDaniel H. Van Raalte
Daniel H. Van Raalte
RCRicardo Correa‐Rotter
Ricardo Correa‐Rotter
RTRobert D. Toto
Robert D. Toto
HHHiddo Heerspink
Hiddo Heerspink
BSBergur V. Stefánsson
Bergur V. Stefánsson
Aims Renin‐angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium–glucose co‐transporter‐2 inhibitors reduce albuminuria and may complement RASi by offering additional renal protection. This post hoc analysis investigated dapagliflozin's effects on cardiac/renal risk factors in patients with type 2 diabetes (T2D) with increased albuminuria treated with or without RASi at baseline. Materials and Methods We evaluated the effects of dapagliflozin 10 mg/day over 12‐24 weeks across 13 placebo‐controlled studies in patients with T2D with urinary albumin‐to‐creatinine ratio (UACR) ≥30 mg/g at baseline. Patients were divided into two subgroups based on treatment with or without RASi at baseline. Results Compared with patients with RASi at baseline (n=957), patients without RASi (n=302) were younger, had a shorter duration of diabetes (7 vs. 12 years), higher eGFR, and lower UACR, serum uric acid (sUA), body weight, and systolic blood pressure. Placebo‐adjusted treatment effects of dapagliflozin on UACR, eGFR, HbA1c, and haematocrit over 24 weeks were similar across groups. Mean reductions in body weight and sUA were more distinct in patients without RASi treatment at baseline. Conclusions Treatment with dapagliflozin over 24 weeks provides similar clinically relevant improvements in metabolic and haemodynamic parameters, and similar reductions in UACR, in patients with T2D with elevated albuminuria treated with or without RASi at baseline.

27 November 2024 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
DLDAVID LEON-JIMENEZ
DAVID LEON-JIMENEZ
VSVikas S Sridhar
Vikas S Sridhar
MLManuel López-Mendoza
Manuel López-Mendoza
RSRosalie A Scholtes
Rosalie A Scholtes
RSRoland E Schmieder
Roland E Schmieder
EBErik J M van Bommel
Erik J M van Bommel
The progressive loss of kidney function in diabetes mellitus is partly attributable to the occurrence of glomerular hyperfiltration. Consequently, therapeutic interventions that lower intra-glomerular pressure are a cornerstone of treatment in diabetic kidney disease. Sodium-glucose cotransporter 2 (SGLT2) inhibitors consistently reduce glomerular filtration rate (GFR) and calculated intraglomerular pressures across studies. However, the net effect on arteriolar tone that leads to acute GFR declines may differ between cohorts. While pre-glomerular vasoconstriction appears to be the dominant mechanism responsible for GFR dipping in patients with type 1 diabetes (T1D) and glomerular hyperfiltration, other factors, including post-glomerular vasodilation, may contribute to the acute GFR decline in normofilterering individuals with T1D and type 2 diabetes. Regardless of the responsible mechanisms, acute changes in GFR are associated with long-term kidney function preservation—a relationship that may reflect an underlying protective decline in glomerular hypertension.